{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:49Z","timestamp":1791078889508,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020331","name":"Minophagen Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40268-024-00465-7","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T18:05:22Z","timestamp":1718301922000},"page":"227-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-3011","authenticated-orcid":false,"given":"Akimasa","family":"Sanagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Furukawa-Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713\u201322. https:\/\/doi.org\/10.1182\/blood-2007-03-055749.","journal-title":"Blood"},{"key":"465_CR2","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064\u201373. https:\/\/doi.org\/10.1182\/blood-2008-10-184168.","journal-title":"Blood"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archderm.143.7.854","volume":"143","author":"VD Criscione","year":"2007","unstructured":"Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002. Arch Dermatol. 2007;143:854\u20139. https:\/\/doi.org\/10.1001\/archderm.143.7.854.","journal-title":"Arch Dermatol"},{"key":"465_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107:265\u201376. https:\/\/doi.org\/10.1182\/blood-2005-06-2508.","journal-title":"Blood"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.12299","volume":"41","author":"T Hamada","year":"2014","unstructured":"Hamada T, Iwatsuki K. Cutaneous lymphoma in Japan: a nationwide study of 1733 patients. J Dermatol. 2014;41:3\u201310. https:\/\/doi.org\/10.1111\/1346-8138.12299.","journal-title":"J Dermatol"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1346-8138.16289","volume":"49","author":"K Yonekura","year":"2022","unstructured":"Yonekura K. Current treatment strategies and emerging therapies for cutaneous lymphoma. J Dermatol. 2022;49:223\u201331. https:\/\/doi.org\/10.1111\/1346-8138.16289.","journal-title":"J Dermatol"},{"key":"465_CR7","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/1346-8138.15707","volume":"48","author":"M Ohtsuka","year":"2021","unstructured":"Ohtsuka M, Hamada T, Miyagaki T, Shimauchi T, Yonekura K, Kiyohara E, et al. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol. 2021;48:e49-71. https:\/\/doi.org\/10.1111\/1346-8138.15707.","journal-title":"J Dermatol"},{"key":"465_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180:496\u2013526. https:\/\/doi.org\/10.1111\/bjd.17240.","journal-title":"Br J Dermatol"},{"key":"465_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organization for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update. Eur J Cancer. 2017;77:57\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.027.","journal-title":"Eur J Cancer"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv30\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdy133.","journal-title":"Ann Oncol"},{"key":"465_CR11","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results. J Clin Oncol. 2001;19:2456\u201371. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2456.","journal-title":"J Clin Oncol"},{"key":"465_CR12","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581\u201393.","journal-title":"Arch Dermatol"},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/1346-8138.16801","volume":"50","author":"A Sanagawa","year":"2023","unstructured":"Sanagawa A, Hayakawa T, Nishida E, Yamamoto A, Ikumi K, Mori Y, et al. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: a post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma. J Dermatol. 2023;50:917\u201326. https:\/\/doi.org\/10.1111\/1346-8138.16801.","journal-title":"J Dermatol"},{"key":"465_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-021-00655-0","volume":"12","author":"A Morita","year":"2022","unstructured":"Morita A, Tateishi C, Ikumi K, Hayashi D, Nakada A, Nishihara H, et al. Comparison of the efficacy and safety of bexarotene and photo(chemo)therapy combination therapy and bexarotene monotherapy for cutaneous T-cell lymphoma. Dermatol Ther (Heidelb). 2022;12:615\u201329. https:\/\/doi.org\/10.1007\/s13555-021-00655-0.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"465_CR15","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1253\/circj.CJ-16-1087","volume":"80","author":"A Goda","year":"2016","unstructured":"Goda A, Masuyama T. Obesity and overweight in Asian people. Circ J. 2016;80:2425\u20136. https:\/\/doi.org\/10.1253\/circj.CJ-16-1087.","journal-title":"Circ J"},{"key":"465_CR16","doi-asserted-by":"publisher","unstructured":"Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for \u2018obesity disease\u2019 in Japan. Circ J. 2002;66:987\u201392. https:\/\/doi.org\/10.1253\/circj.66.987","DOI":"10.1253\/circj.66.987"},{"key":"465_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/sj.ijo.0802486","volume":"28","author":"K Shiwaku","year":"2004","unstructured":"Shiwaku K, Anuurad E, Enkhmaa B, Nogi A, Kitajima K, Shimono K, et al. Overweight Japanese with body mass indexes of 23.0\u201324.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. Int J Obes Relat Metab Disord. 2004;28:152\u20138. https:\/\/doi.org\/10.1038\/sj.ijo.0802486.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"465_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ced.13044","volume":"42","author":"I Cabello","year":"2017","unstructured":"Cabello I, Servitje O, Corbella X, Bard\u00e9s I, Pint\u00f3 X. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clin Exp Dermatol. 2017;42:276\u201381. https:\/\/doi.org\/10.1111\/ced.13044.","journal-title":"Clin Exp Dermatol"},{"key":"465_CR19","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamadermatol.2018.3679","volume":"154","author":"I Cabello","year":"2018","unstructured":"Cabello I, Alia P, Pint\u00f3 X, Muniesa C, Fernandez-de-Misa R, Pe\u00f1ate Y, et al. Association of APOA5 and APOC3 genetic polymorphisms with severity of hypertriglyceridemia in patients with cutaneous T-cell lymphoma treated with bexarotene. JAMA Dermatol. 2018;154:1424\u201331. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3679.","journal-title":"JAMA Dermatol"},{"key":"465_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/oby.23639","volume":"31","author":"Z Li","year":"2023","unstructured":"Li Z, Daniel S, Fujioka K, Umashanker D. Obesity among Asian American people in the United States: a review. Obesity (Silver Spring). 2023;31:316\u201328. https:\/\/doi.org\/10.1002\/oby.23639.","journal-title":"Obesity (Silver Spring)"},{"key":"465_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25:521\u201338. https:\/\/doi.org\/10.5551\/jat.44412.","journal-title":"J Atheroscler Thromb"},{"key":"465_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/1346-8138.16201","volume":"49","author":"T Hamada","year":"2022","unstructured":"Hamada T, Morita A, Suga H, Boki H, Fujimura T, Hirai Y, et al. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: real-world experience from post-marketing surveillance. J Dermatol. 2022;49:253\u201362. https:\/\/doi.org\/10.1111\/1346-8138.16201.","journal-title":"J Dermatol"},{"key":"465_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bjd.12042","volume":"168","author":"JJ Scarisbrick","year":"2013","unstructured":"Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168:192\u2013200. https:\/\/doi.org\/10.1111\/bjd.12042.","journal-title":"Br J Dermatol"},{"key":"465_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2340\/00015555-1359","volume":"92","author":"L V\u00e4kev\u00e4","year":"2012","unstructured":"V\u00e4kev\u00e4 L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012;92:258\u201363. https:\/\/doi.org\/10.2340\/00015555-1359.","journal-title":"Acta Derm Venereol"},{"key":"465_CR25","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.718","volume":"102","author":"J Rouanet","year":"2022","unstructured":"Rouanet J, Joulie I, Lambert C, D\u2019Incan M. Real-life use of bexarotene for T-cell cutaneous lymphoma management: efficacy and tolerance with low doses. Acta Derm Venereol. 2022;102: adv00746. https:\/\/doi.org\/10.2340\/actadv.v102.718.","journal-title":"Acta Derm Venereol"},{"key":"465_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/1346-8138.15322","volume":"47","author":"T Fujimura","year":"2020","unstructured":"Fujimura T, Sato Y, Tanita K, Amagai R, Shimauchi T, Ogata D, et al. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. J Dermatol. 2020;47:636\u201340. https:\/\/doi.org\/10.1111\/1346-8138.15322.","journal-title":"J Dermatol"},{"key":"465_CR27","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1111\/jdv.15661","volume":"33","author":"A Pileri","year":"2019","unstructured":"Pileri A, Fava P, Fuligni F, Gunnella S, Guglielmo A, Astrua C, et al. Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. J Eur Acad Dermatol Venereol. 2019;33:e367\u20139. https:\/\/doi.org\/10.1111\/jdv.15661.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"465_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","volume":"155","author":"C Assaf","year":"2006","unstructured":"Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006;155:261\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07329.x.","journal-title":"Br J Dermatol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00465-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T10:27:38Z","timestamp":1723199258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00465-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00465-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"23 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Minophagen Pharmaceutical Co., Ltd, Tokyo, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Akimichi Morita has received research grants and speakers\u2019 fees from Minophagen Pharmaceutical Co., Ltd. Akimasa Sanagawa, Tomoaki Hayakawa, Aya Yamamoto, Yuji Hotta, and Yoko Furukawa-Hibi have no conflicts of interest to declare in relation to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study included a post hoc analysis of data obtained from a previous clinical trial (jRCTs041180094) that was approved by the Ethics Review Boards of Nagoya City University and Osaka City University. All procedures conducted during studies involving human participants were performed in accordance with the ethical standards of the institutional research committee and the 1964 Declaration of Helsinki and its later amendments, as well as with comparable ethical standards. No new samples or clinical or laboratory data were generated during the present study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent prior to any study procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AS: Conception and design of the study; data acquisition, analysis and interpretation; drafting the manuscript. TH: Study design; data acquisition, analysis, and interpretation; support for manuscript writing and review. AY: Data acquisition, support for manuscript writing and review. YH: Data interpretation, support for manuscript writing and review. YF: Data interpretation, support for manuscript writing and review. AM: Study design, data acquisition, supervision and support for manuscript writing and review. All authors read and approved the final version of this manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}